Glioblastoma Multiforme Treatment Market Overview
Glioblastoma, commonly known as glioblastoma multiforme (GBM), is one of the most aggressive and lethal brain cancers currently claiming the lives of many people. More than 20% of all deaths due to brain tumours are caused by this condition. The patient with this disease has a life expectancy of less than 14 months, and death is as painful as it can be. Researchers and pharmaceutical companies are working to produce treatments that will extend the lives of patients in order to lessen the number of deaths. Furthermore, there have been significant advancements in the realm of procedures to remove the tumour produced by glioblastoma multiforme (GBM). As a result of these changes, the global Glioblastoma Multiforme Treatment market is predicted to have strong growth in the forecasted period.
According to research published by the National Center for Biotechnology Information in 2023, the rate of glioblastoma cases increased to 3.19 per 100,000 in 2017. This is a concerning growth rate, as the death rate from this condition has risen at an exponential pace. This increase necessitates the development of therapies and medications that lower the number of fatalities among patients while also increasing their life expectancy. In the projected period, the increased demand for such medications would be the primary driver of the global Glioblastoma Multiforme Treatment market.
Governments are spending money in the research and application of innovative technologies that can help accelerate glioblastoma drug development. These advancements in healthcare infrastructure also increase demand for novel glioblastoma drugs, which is another factor expected to drive the global Glioblastoma Multiforme Treatment market upwards in the estimated period.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Treatment, Drug Class, End User, and Region. |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.) |
Covid-19 Impact on Glioblastoma Multiforme Treatment Market
In addition, the current Glioblastoma Multiforme Treatment Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Glioblastoma Multiforme Treatment Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Glioblastoma Multiforme Treatment Market Segment Overview
According to Treatment, the Radiation Therapy segment holds the largest share in the global Glioblastoma Multiforme Treatment market. This is because survival rates have improved. Radiation therapy can be used as a stand-alone treatment or in combination with chemotherapy and surgery. In the event of a recurrence of a brain tumour, it is also beneficial and highly recommended. When temozolomide is used with radiotherapy, the tumour becomes more sensitive to radiation. This combination of treatments is more successful than radiotherapy alone.Furthermore, the most common treatment for GBM is surgery, which is followed by radiation therapy and chemotherapy.
Glioblastoma Multiforme Treatment Market, By Treatment
· Surgery
· Radiation Therapy
· Chemotherapy
· Targeted Therapy
· Tumor Treating Field (TTF) Therapy
· Immunotherapy
Glioblastoma Multiforme Treatment Market, By Drug Class
· Temozolomide
· Bevacizumab
· Lomustine
· Carmustine Wafers
· Others
Glioblastoma Multiforme Treatment Market, By End User
· Hospitals
· Clinics
· Ambulatory Surgical Centers
Glioblastoma Multiforme Treatment Regional Overview
Geographically, North America is the most prominent region for the Glioblastoma Multiforme Treatment market. The region is anticipated to continue its domination in the coming years. This is due to the presence and rise of several pharmaceutical companies dedicated to the development of glioblastoma-curing drugs. Moreover, due to several factors such as the introduction of generic temozolomide, an improved economy, a growing senior population, and increased healthcare investment, Asia Pacific is predicted to grow at the quickest rate over the projection period.
Glioblastoma Multiforme Treatment Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Glioblastoma Multiforme Treatment Market Competitor overview
Some key developments and strategies adopted by manufacturers in Glioblastoma Multiforme Treatment are highlighted below.
· In May 2023, Merck, known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).
Glioblastoma Multiforme Treatment Market, Key Players
· Merck & Co., Inc.
· Amgen, Inc.
· F. Hoffmann-La Roche Ltd.
· Pfizer Inc.
· Amgen, Inc.
· Teva Pharmaceutical Industries Ltd.
· Sun Pharmaceutical Industries Ltd.
· Arbor Pharmaceuticals, LLC
· Amneal Pharmaceuticals
· Karyopharm Therapeutics, Inc.
· Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Frequently Asked Questions (FAQ) :
Q1. Which are the parts of the Drug Class segment in the global Glioblastoma Multiforme Treatment market?
Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others are parts of the Drug Class segment in the global Glioblastoma Multiforme Treatment market
Q2. Which Segments are covered in the global Glioblastoma Multiforme Treatment Market report?
Treatment, Drug Class, End User, and Region. these segments are covered in the global Glioblastoma Multiforme Treatment market report.
Q3. Which segment is projected to hold the largest share in the global Glioblastoma Multiforme Treatment Market?
Radiation Therapy segment is projected to hold the largest share in the global Glioblastoma Multiforme Treatment Market.
Q4. Which region holds the largest share in the global Glioblastoma Multiforme Treatment market?
North America held the largest share in the global Glioblastoma Multiforme Treatment market
Q5. Which are the prominent players in the global Glioblastoma Multiforme Treatment Market?
Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.) are some key players in the global Glioblastoma Multiforme Treatment Market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Glioblastoma Multiforme Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Treatment
- 5.2.1. Surgery
- 5.2.2. Radiation Therapy
- 5.2.3. Chemotherapy
- 5.2.4. Targeted Therapy
- 5.2.5. Tumor Treating Field (TTF) Therapy
- 5.2.6. Immunotherapy
- 5.3. Market Analysis, Insights and Forecast – By Drug Class
- 5.3.1. Temozolomide
- 5.3.2. Bevacizumab
- 5.3.3. Lomustine
- 5.3.4. Carmustine Wafers
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By End User
- 5.4.1. Hospitals
- 5.4.2. Clinics
- 5.4.3. Ambulatory Surgical Centers
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Glioblastoma Multiforme Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Treatment
- 6.2.1. Surgery
- 6.2.2. Radiation Therapy
- 6.2.3. Chemotherapy
- 6.2.4. Targeted Therapy
- 6.2.5. Tumor Treating Field (TTF) Therapy
- 6.2.6. Immunotherapy
- 6.3. Market Analysis, Insights and Forecast – By Drug Class
- 6.3.1. Temozolomide
- 6.3.2. Bevacizumab
- 6.3.3. Lomustine
- 6.3.4. Carmustine Wafers
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By End User
- 6.4.1. Hospitals
- 6.4.2. Clinics
- 6.4.3. Ambulatory Surgical Centers
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Glioblastoma Multiforme Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Treatment
- 7.2.1. Surgery
- 7.2.2. Radiation Therapy
- 7.2.3. Chemotherapy
- 7.2.4. Targeted Therapy
- 7.2.5. Tumor Treating Field (TTF) Therapy
- 7.2.6. Immunotherapy
- 7.3. Market Analysis, Insights and Forecast – By Drug Class
- 7.3.1. Temozolomide
- 7.3.2. Bevacizumab
- 7.3.3. Lomustine
- 7.3.4. Carmustine Wafers
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By End User
- 7.4.1. Hospitals
- 7.4.2. Clinics
- 7.4.3. Ambulatory Surgical Centers
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Glioblastoma Multiforme Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Treatment
- 8.2.1. Surgery
- 8.2.2. Radiation Therapy
- 8.2.3. Chemotherapy
- 8.2.4. Targeted Therapy
- 8.2.5. Tumor Treating Field (TTF) Therapy
- 8.2.6. Immunotherapy
- 8.3. Market Analysis, Insights and Forecast – By Drug Class
- 8.3.1. Temozolomide
- 8.3.2. Bevacizumab
- 8.3.3. Lomustine
- 8.3.4. Carmustine Wafers
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By End User
- 8.4.1. Hospitals
- 8.4.2. Clinics
- 8.4.3. Ambulatory Surgical Centers
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Glioblastoma Multiforme Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Treatment
- 9.2.1. Surgery
- 9.2.2. Radiation Therapy
- 9.2.3. Chemotherapy
- 9.2.4. Targeted Therapy
- 9.2.5. Tumor Treating Field (TTF) Therapy
- 9.2.6. Immunotherapy
- 9.3. Market Analysis, Insights and Forecast – By Drug Class
- 9.3.1. Temozolomide
- 9.3.2. Bevacizumab
- 9.3.3. Lomustine
- 9.3.4. Carmustine Wafers
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By End User
- 9.4.1. Hospitals
- 9.4.2. Clinics
- 9.4.3. Ambulatory Surgical Centers
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Merck & Co., Inc.
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Amgen, Inc.
- 10.6. F. Hoffmann-La Roche Ltd.
- 10.7. Pfizer Inc.
- 10.8. Amgen, Inc.
- 10.9. Teva Pharmaceutical Industries Ltd.
- 10.10. Sun Pharmaceutical Industries Ltd.
- 10.11. Arbor Pharmaceuticals, LLC
- 10.12. Amneal Pharmaceuticals
- 10.13. Karyopharm Therapeutics, Inc.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
